663. Structure function relationship in thrombin activatable fibrinolysis inhibitor 645. Platelet immunoreceptor tyrosine based activation motif (ITAM) and hemITAM signaling and vascular integrit…
865 Coagulopathy and its management in patients with severe 875 Periprocedural management of patients receiving a vitamin K antagonist or a direct oral anticoagulant requiring an elective procedur…
421. Biosimilars of low molecular weight heparin products fostering competition or reducing biodiversity 427 contact system revisited an interface between inflamation coagulation and innate immun…
231. Shock, acute disseminated intravascular coagulation and microvascular thrombosis is shock liver the unrecognized provocateur of ischemic limb necrosis 236. Structural and functional insights …
3. International society on thrombosis and haemotosis core curiculum project core competencies in clinical thrombosis and hemostasis 28. The contact activation and kalikrein/kinin systems pathophy…
2152. Revisiting the tale of venous thromboembolism in hospitalized medical patients 2155. Central venous catheters and upper extremity deep vein thrombosis (MITH) study 2161. Bemiparin for thro…
1949. Spatiotemporal regulation of coagulation and platelet activation during the hemostatic response in vivo 1960. A critical qppraisal of point of care coagulation testing in critically ill pati…
1365. Global public awarness of venous thromboembolism 1372. Venous thrombosis and cancer from mouse models to clinical trials 1383. Factor XI and contact activation as targets for anthitrombotic…
1175. Management of superficial vein thrombosis 1184. Hemophilia B molecular pathogenesis and mutation analysis 1196. Anticoagulation management during multivessel coronary artery bypass graftin…
893. Human platelet IgG Fc receptor FcyRIIA in immunity and thrombosis 909. Dysfibrinogemia from molecular anomalies to clinical manifestations and management 920. Does the response to aspirin a…